Calidi Biotherapeutics, Inc. (CLDI)
NYSEAMERICAN: CLDI · Real-Time Price · USD
0.2845
-0.0105 (-3.56%)
At close: Mar 24, 2026, 4:00 PM EDT
0.2821
-0.0024 (-0.84%)
After-hours: Mar 24, 2026, 4:49 PM EDT
Calidi Biotherapeutics Revenue
Revenue (ttm)
n/a
Revenue Growth
n/a
P/S Ratio
n/a
Revenue / Employee
n/a
Employees
28
Market Cap
2.04M
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | - | - | - |
| Dec 31, 2023 | - | - | - |
| Dec 31, 2022 | 45.00K | -404.00K | -89.98% |
| Dec 31, 2021 | 449.00K | - | - |
| Dec 31, 2020 | - | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Jaguar Health | 11.79M |
| Ensysce Biosciences | 4.49M |
| 60 Degrees Pharmaceuticals | 1.36M |
| Scinai Immunotherapeutics | 1.15M |
| Onconetix | 815.37K |
| HCW Biologics | 422.03K |
| BioRestorative Therapies | 383.40K |
CLDI News
- 12 days ago - Calidi Biotherapeutics Presents its Innovative and Scalable Manufacturing Process for CLD-401 at the 9th Annual Bioprocessing Summit; FDA Feedback Support Company's Approach to Manufacturing - GlobeNewsWire
- 14 days ago - Calidi Biotherapeutics Announces Closing of $6.0 Million Underwritten Public Offering and Full Exercise of Underwriters' Over-Allotment Option - GlobeNewsWire
- 18 days ago - Calidi Biotherapeutics Announces Pricing of $5.2 Million Underwritten Public Offering - GlobeNewsWire
- 18 days ago - Calidi Biotherapeutics Announces Proposed Public Offering - GlobeNewsWire
- 4 weeks ago - Calidi Biotherapeutics Presents Data on its New Approach to Bispecific T-Cell Engagers (BiTEs) Using its RedTail Platform at the 2026 AACR-IO Conference - GlobeNewsWire
- 5 weeks ago - Calidi Biotherapeutics To Present on its New Approach to Bispecific T-Cell Engagers (BiTEs) Using its RedTail Platform in a Late-Breaking Abstract at the 2026 AACR-IO Conference - GlobeNewsWire
- 4 months ago - Calidi Biotherapeutics Announces Exclusive Live Investor Webinar and Q&A Session on November 19, 2025 - GlobeNewsWire
- 4 months ago - Calidi Biotherapeutics Reports Third Quarter 2025 Financial Results and Recent Operational Highlights - GlobeNewsWire